Proportion achieving SVR12 among GT1, treatment-naïve, non-cirrhotic patients on LDV/SOF or SOF/VEL treated at a single centre in Germany.

Abstract

LDV: ledipasvir; SOF: sofosbuvir; SVR12: sustained virological response at 12 weeks; VEL: velpatasvir.</p